Blood test for cancer detection company Grail rakes in $390M in latest round
Just over a week after Third Rock-backed Thrive unveiled ‘real world’ data from a large study evaluating the ability of its blood test to sniff out early signs of cancer in individuals with no history of the disease, rival Grail has raised a gargantuan $390 million in its latest round of financing.
Grail — which was carved out of the DNA sequencing company Illumina in 2016 — has a multi-cancer detection blood test that relies on DNA sequencing to assess methylation, an epigenetic change across the genome to expose cancer signals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.